Related Experiment Videos
Rapid inhibition of interleukin-6 signaling and Stat3 activation mediated by mitogen-activated protein kinases
T K Sengupta1, E S Talbot, P A Scherle
1Department of Medicine, Hospital for Special Surgery, Cornell University Graduate School of Medical Sciences New York, NY 10021, USA.
Abstract:
Gene activation and cellular differentiation induced by interleukin-6 (IL-6) and transcription factor Stat3 are suppressed by several factors, including ionomycin, granulocyte/macrophage-colony-stimulating factor, and phorbol 12-myristate 13-acetate (PMA), that block IL-6-induced Stat3 activation. These inhibitory agents activate mitogen activated protein kinases (MAPKs), and thus the role of MAPKs in the mechanism of inhibition of Stat3 activation was investigated. Inhibition of IL-6-induced Stat3 activation by PMA and ionomycin was rapid (within 5 min) and did not require new RNA or protein synthesis. Inhibition of Stat3 DNA-binding activity and tyrosine phosphorylation by PMA, ionomycin, and granulocyte/macrophage-colony-stimulating factor was reversed when activation of the extracellular signal-regulated kinase (ERK) group of MAPKs was blocked by using specific kinase inhibitors. Expression of constitutively active MEK1, the kinase that activates ERKs, or overexpression of ERK2, but not JNK1, inhibited Stat3 activation. Inhibition of Stat3 correlated with suppression of IL-6-induction of a signal transducer and activator of transcription (STAT)-dependent reporter gene. In contrast to IL-6, activation of Stat3 by interferon-alpha was not inhibited. MEKs and ERKs inhibited IL-6 activation of Stat3 harboring a mutation at serine-727, the major site for serine phosphorylation, similar to inhibition of wild-type Stat3, and inhibited Janus kinases Jak1 and Jak2 upstream of Stat3 in the Jak-STAT-signaling pathway. These results demonstrate an ERK-mediated mechanism for inhibiting IL-6-induced Jak-STAT signaling that is rapid and inducible, and thus differs from previously described mechanisms for downmodulation of the Jak-STAT pathway. This inhibitory pathway provides a molecular mechanism for the antagonism of Stat3-mediated IL-6 activity by factors that activate ERKs.
Insights
Certain factors rapidly inhibit interleukin-6 (IL-6) signaling by activating mitogen-activated protein kinases (MAPKs), specifically extracellular signal-regulated kinases (ERKs), which block the transcription factor Stat3 activation. This ERK-mediated pathway offers a new understanding of Jak-STAT signaling regulation.
Area of Science:
- Molecular Biology
- Cell Signaling
- Immunology
Background:
- Interleukin-6 (IL-6) signaling, mediated by transcription factor Stat3, is crucial for gene activation and cellular differentiation.
- Several agents, including phorbol 12-myristate 13-acetate (PMA) and ionomycin, suppress IL-6-induced Stat3 activation.
- These inhibitory agents activate mitogen-activated protein kinases (MAPKs), suggesting their involvement in Stat3 inhibition.
Purpose of the Study:
- To investigate the role of MAPKs in the mechanism of Stat3 activation inhibition by IL-6.
- To elucidate the specific MAPK pathway involved in the antagonism of IL-6-mediated Stat3 activity.
Main Methods:
- Investigated the rapid inhibition of IL-6-induced Stat3 activation by PMA and ionomycin.
- Utilized specific kinase inhibitors to block extracellular signal-regulated kinase (ERK) activation.
- Examined the effects of expressing constitutively active MEK1 or ERK2 on Stat3 activation.
Main Results:
- Inhibition of IL-6-induced Stat3 activation by PMA and ionomycin was rapid and did not require new protein synthesis.
- Blocking ERK activation reversed the inhibition of Stat3 DNA-binding activity and tyrosine phosphorylation.
- Expression of MEK1 or ERK2, but not JNK1, inhibited Stat3 activation, correlating with suppressed STAT-dependent reporter gene expression.
Conclusions:
- Demonstrated an ERK-mediated mechanism for inhibiting IL-6-induced Jak-STAT signaling.
- This inhibitory pathway is rapid, inducible, and distinct from previously known mechanisms.
- Provides a molecular basis for the antagonism of Stat3-mediated IL-6 activity by ERK-activating factors.